Richard Briscoe

Richard Briscoe currently serves as Senior Vice President of Safety Assessment & Research Operations at AbbVie, a position held since August 2024. Prior to this, Richard was with Cerevel Therapeutics from July 2019 until its acquisition by AbbVie in August 2024, where Richard held the role of Senior Vice President, Drug Target Lead/Safety Assessment and Research Operations. Richard's extensive experience includes nearly 17 years at Merck, where Richard advanced from Director of the Pre-Clinical Safety Assessment to Senior Vice President, overseeing safety assessments within the Neuroscience and Ophthalmology franchises. Additional roles include Director of the Strategy Development Group at Merck, and Director of Safety Pharmacology at the University of Michigan. Richard holds a PhD from the University of Oklahoma Health Sciences Center and a B.S. in Psychology/Biology from Central Michigan University.